HVB MINI FUTURE BULL - ASTRAZENECA | Real-time Bid/Ask 08:24:38 29/04/2024 pm IST | ||
| 6.47 EUR / 6.48 EUR | +0.54% |
|
| Current month | +30.63% | ||
| 1 month | +40.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 6.61 | +2.64% | 0 |
| 26/24/26 | 6.44 | +0.63% | 0 |
| 25/24/25 | 6.4 | +13.88% | 0 |
| 24/24/24 | 5.62 | +2.18% | 0 |
| 23/24/23 | 5.5 | -1.43% | 0 |
Delayed Quote Börse Stuttgart
Last update April 29, 2024 at 06:29 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TXX |
| ISIN | DE000HR5TXX4 |
| Date issued | 25/02/2021 |
| Strike | 6,512 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.97 € |
|---|---|
| Lowest since issue | 1.06 € |
| Spread | 0.01 € |
| Spread % | 0.15% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
149.3
USD
Average target price
164.3
USD
Spread / Average Target
+10.02%
- Stock Market
- Certificates
- Certificat
